179 related articles for article (PubMed ID: 15947683)
1. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.
Xin Y; Lyness G; Chen D; Song S; Wientjes MG; Au JL
J Urol; 2005 Jul; 174(1):322-7. PubMed ID: 15947683
[TBL] [Abstract][Full Text] [Related]
2. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Song S; Yu B; Wei Y; Wientjes MG; Au JL
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6058-65. PubMed ID: 15447990
[TBL] [Abstract][Full Text] [Related]
3. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
4. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Song S; Wientjes MG; Walsh C; Au JL
Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
[TBL] [Abstract][Full Text] [Related]
5. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
Braunschweiger PG; Jones SA; Johnson CS; Furmanski P
Cancer Res; 1991 Oct; 51(20):5454-60. PubMed ID: 1913664
[TBL] [Abstract][Full Text] [Related]
7. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
8. Enhanced sensitivity to mitomycin C by abating heat shock protein 70 expression in human bladder cancer cell line of BIU-87.
He LF; Guan KP; Yan Z; Ye HY; Xu KX; Ren L; Hou SK
Chin Med J (Engl); 2005 Dec; 118(23):1965-72. PubMed ID: 16336832
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of mitomycin C in cultured human bladder tumors.
Schmittgen TD; Wientjes MG; Badalament RA; Au JL
Cancer Res; 1991 Aug; 51(15):3849-56. PubMed ID: 1906778
[TBL] [Abstract][Full Text] [Related]
10. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Lu Z; Wientjes TS; Au JL
Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with a methionine-mitomycin C conjugate and a methionine-deficient diet on tumor growth.
Yoshida S; Yamana H; Tanaka T; Ishibashi N; Toh U; Ishii H; Shirouzu Y; Shirouzu K
In Vivo; 1998; 12(3):351-5. PubMed ID: 9706483
[TBL] [Abstract][Full Text] [Related]
12. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
[TBL] [Abstract][Full Text] [Related]
13. A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids.
Burgués JP; Gómez L; Pontones JL; Vera CD; Jiménez-Cruz JF; Ozonas M
Eur Urol; 2007 Apr; 51(4):962-9; discussion 969-70. PubMed ID: 17084017
[TBL] [Abstract][Full Text] [Related]
14. Penetration of mitomycin C in human bladder.
Wientjes MG; Badalament RA; Wang RC; Hassan F; Au JL
Cancer Res; 1993 Jul; 53(14):3314-20. PubMed ID: 8324743
[TBL] [Abstract][Full Text] [Related]
15. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
[TBL] [Abstract][Full Text] [Related]
16. Development of a human xenograft model for the evaluation of monoclonal antibody L6-mitomycin immunoconjugates.
Trail PA; Rose WC
In Vivo; 1989; 3(5):319-24. PubMed ID: 2519872
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
18. [Effects of IgG-Fc-mitomycin C conjugate on cancer cells].
Baba E
Hokkaido Igaku Zasshi; 1996 Mar; 71(2):271-81. PubMed ID: 8641681
[TBL] [Abstract][Full Text] [Related]
19. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
20. Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
Kodama N; Murata Y; Asakawa A; Inui A; Hayashi M; Sakai N; Nanba H
Nutrition; 2005 May; 21(5):624-9. PubMed ID: 15850970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
